The US Food and Drug Administration (FDA) has accepted Bristol Myers Squibb’s (BMS) supplemental new drug application (sNDA) for Camzyos (mavacamten) to treat adolescents aged 12 to under 18 years with symptomatic obstructive hypertrophic cardiomyopathy (oHCM).
Under the collaboration, the company will partner with the MD Anderson scientists on preclinical trials for further validating TransCode’s RNA-targeted oncology therapy and diagnostic candidates. They will also
The investigational human monoclonal antibody, OMS906 targets mannan-binding lectin-associated serine protease-3 (MASP-3), the main activator of the alternative pathway of the complement system. MASP-3 converts pro-complement factor D
Healthcare venture capital firm Lapam Capital, investment management firm Junson Capital and Dyee Capital have led the financing round. BridGene’s IMTAC platform combines ‘cutting-edge’ technologies including chemical proteomics,
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.
